Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica Remedia's book value per share for the quarter that ended in Mar. 2026 was lei0.85.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Farmaceutica Remedia was 21.40% per year. The lowest was -1.60% per year. And the median was 5.80% per year.
Farmaceutica Remedia (LTS:0M8I) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Farmaceutica Remedia Book Value per Share Related Terms
Farmaceutica Remedia Book Value per Share Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0M8I vs MCK, COR, CAH: Book Value per Share Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's PB Ratio distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmaceutica Remedia (LTS:0M8I) has a Book Value per Share of lei0.85 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Farmaceutica Remedia and its competitors.
Is Farmaceutica Remedia's Book Value per Share too high?
Farmaceutica Remedia's current Book Value per Share is lei0.85. Overall, Farmaceutica Remedia has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Book Value per Share compare to MCK and COR?
Farmaceutica Remedia's Book Value per Share of lei0.85 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Medical Distribution company?
A good Book Value per Share depends on the Medical Distribution industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Farmaceutica Remedia and its competitors. Farmaceutica Remedia's current Book Value per Share is lei0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Farmaceutica Remedia (LTS:0M8I) has a current Book Value per Share of lei0.85. The stock's GF Value™ is lei0.23, compared to a current price of lei0.25 — trading 8.7% above its estimated fair value. The current Book Value per Share is lei0.85. Farmaceutica Remedia's overall GF Score™ is 59/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Farmaceutica Remedia (LTS:0M8I), the current Book Value per Share is lei0.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (LTS:0M8I) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.25 is trading 8.7% above its estimated GF Value™ of lei0.23.
Key valuation signals for LTS:0M8I:
Book Value per Share: lei0.85
GF Value™: lei0.23 vs. price of lei0.25 (8.7% above fair value)
No single metric tells the full story. See the LTS:0M8I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
59GF Score
Get the complete analysis for LTS:0M8I
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M8I has been successfully added to your 
